Why is Cohance Life falling/rising?

As of 18-Jul, Cohance Lifesciences Ltd's stock is currently priced at 1,071.50, reflecting a decline of 48.5 points or 4.33%. Today's price summary indicates that the stock has underperformed its sector by 3.78% and has experienced a trend reversal after seven consecutive days of gains. The stock touched an intraday low of Rs 1,071.50, and the weighted average price suggests that more volume was traded close to this low price. Despite a positive performance over the past year, with a return of 23.27%, the company faces challenges such as a significant drop in quarterly profits and poor long-term growth, as indicated by a -3.76% annual rate in operating profit over the last five years. Additionally, the stock's high valuation, with a Price to Book Value of 24.2, compared to its peers, may be contributing to the recent price decline.
In the broader market context, the stock has shown a positive return of 6.19% over the past week, while the benchmark Sensex has declined by 0.90%. However, the year-to-date performance shows that Cohance Lifesciences Ltd has underperformed the benchmark, with a decline of 5.46% compared to the Sensex's gain of 4.63%. This contrast highlights the stock's volatility and the impact of its recent poor financial results on investor sentiment, despite its historical market-beating performance. The rising investor participation, indicated by a significant increase in delivery volume, suggests that some investors may still see potential in the stock, but the current negative trends are overshadowing this optimism.